Amedisys Inc (AMED)

Return on equity (ROE)

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (ttm) US$ in thousands 67,780 127,537 112,037 -539 10,307 2,648 2,330 112,184 118,609 120,939 140,303 190,873 209,072 220,176 247,151 201,676 183,608 166,112 128,263 127,331
Total stockholders’ equity US$ in thousands 1,134,540 1,147,760 1,125,200 1,088,180 1,066,510 1,039,910 1,006,780 1,079,120 1,051,570 1,015,740 985,646 966,758 931,351 905,264 874,272 788,153 809,224 756,205 720,851 679,197
ROE 5.97% 11.11% 9.96% -0.05% 0.97% 0.25% 0.23% 10.40% 11.28% 11.91% 14.23% 19.74% 22.45% 24.32% 28.27% 25.59% 22.69% 21.97% 17.79% 18.75%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $67,780K ÷ $1,134,540K
= 5.97%

Amedisys Inc's return on equity (ROE) has exhibited fluctuations over the periods stated. The ROE increased from 18.75% as of March 31, 2020, reaching a peak of 28.27% on June 30, 2021. Subsequently, the ROE declined to 0.23% as of June 30, 2023, before rebounding to 11.11% on September 30, 2024.

Overall, Amedisys Inc's ROE trajectory reflects periods of both growth and decline. A declining ROE can indicate potential inefficiencies in the utilization of shareholder equity, while an increasing ROE suggests improved profitability and efficiency in generating returns for shareholders. The negative ROE experienced in March 31, 2024, may raise concerns and would require further investigation to understand the factors driving this performance.